Aster DM Healthcare Ltd
Healthcare | Small Cap
Aster DM Healthcare shows a mixed financial performance. The company demonstrates strong solvency due to a low debt-to-equity ratio and a reasonable debt ratio, indicating a sound financial structure. Asset growth rate is also very high, suggesting significant investments in the company's future. However, the company's efficiency is notably weak, with low turnover ratios and long receivable days. Growth metrics are also concerning, as revenue, operating profit, and net income growth rates have been inconsistent. Profitability is average, with decent gross and operating margins offset by low returns on capital employed, equity, and assets. Overall, Aster DM Healthcare exhibits financial stability with potential for growth, but needs to improve its operational efficiency and profitability to achieve better financial health.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.80
- Financial Ratio6.60
- Profitability Ratio3.90
- Efficiency Ratio2.00
- Coverage Ratio6.00
- Solvency Ratio10.00
- Liquidity Ratio0.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Aster DM Healthcare shows a mixed financial performance. The company demonstrates strong solvency due to a low debt-to-equity ratio and a reasonable debt ratio, indicating a sound financial structure. Asset growth rate is also very high, suggesting significant investments in the company's future. However, the company's efficiency is notably weak, with low turnover ratios and long receivable days. Growth metrics are also concerning, as revenue, operating profit, and net income growth rates have been inconsistent. Profitability is average, with decent gross and operating margins offset by low returns on capital employed, equity, and assets. Overall, Aster DM Healthcare exhibits financial stability with potential for growth, but needs to improve its operational efficiency and profitability to achieve better financial health.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
97.36
Industry Median
36.13
Small Cap Median
35.79
P/E RATIO
5.87
P/B RATIO
7.22
Industry Median
6.08
Small Cap Median
6.08
P/S RATIO
7.91
Industry Median
5.75
Small Cap Median
5.17
Others
PEG RATIO
-0.81
EV/EBITDA RATIO
5.64
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹631.85 as on Feb 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤30th Apr 26
Standalone Financial Results for the Quarter and Year Ended March 31, 2026
UNDEFINED SENTIMENT
The company's growth ratios present a mixed picture. While asset growth is strong, revenue, operating profit, and net income growth rates are low. This inconsistency indicates the company is investing heavily in assets, but not translating these investments into proportionate revenue and profit growth. Strategies to improve revenue generation and operational efficiency are needed to capitalize on the company's asset base and drive sustainable growth. The high asset growth rate is a positive sign, but it needs to be supported by improved financial performance to ensure long-term success.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 19.11 | -70.8 | 23.55 | 11.87 | 12.2 |
| Operating Profit Growth Rate | 38.98 | -70.84 | 28.64 | 31.13 | 14.59 |
| Earnings Per Share (EPS) Growth | 255.74 | -19.18 | -69.57 | 4056.76 | -93.04 |
| Asset Growth Rate | 7.75 | 18.49 | 21.21 | -63.3 | 22.91 |
| Net Income Growth Rate | 237.64 | -20.97 | -55.37 | 2450.94 | -92.1 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed view. Book value per share is a positive sign, suggesting the company has a solid asset base. However, adjusted and cash earnings per share are average, while dividend per share is low. Capital expenditures are well-managed. Overall, the company needs to improve its earnings and dividend payouts to enhance shareholder value. Effective management of capital expenditures is a strength, needing continued reinforcement to drive long-term financial success.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 13.5 | 10.52 | 5.88 | 6.62 | 9.42 |
| Cash Earnings Per Share (Cash EPS) | 24.84 | 13.34 | 8.64 | 113.14 | 13.34 |
| Book Value Per Share | 71.6 | 81.48 | 83.72 | 61.08 | 88.34 |
| Dividend Per Share (DPS) | 0 | 0 | 120.1 | 5.38 | 3 |
| Capital Expenditures (CapEx) | 544 | 839 | 759 | 355 | 477 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios present a mixed picture. The gross profit margin is good, but the returns on capital employed, equity, and assets are weak. This indicates the company can generate revenue, but its operations are not efficiently converting these revenues into profits. Improving operational efficiency and cost management is essential for boosting overall profitability. The company should focus on strategies to enhance its returns on investments and assets to achieve better financial performance.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 8.7 | 8.52 | 9.6 | 12.2 | 12.92 |
| Return on Capital Employed (ROCE) | 10 | 3 | 4 | 11 | 11 |
| Return on Equity (ROE) | 16.79 | 11.66 | 5.06 | 177.08 | 9.33 |
| Return on Assets (ROA) | 12.24 | 3.01 | 3.2 | 11.42 | 10.65 |
| Operating Margin | 14.95 | 14.93 | 15.54 | 18.22 | 18.61 |
| Net Margin | 5.86 | 15.87 | 5.73 | 130.69 | 9.2 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios suggest significant challenges in asset utilization. Low turnover ratios indicate the company is not effectively generating revenue from its assets or managing its inventory and receivables. Long receivable days further strain working capital management. These inefficiencies can lead to higher costs, reduced profitability, and potential cash flow issues. To improve, the company needs to streamline its operations and optimize its asset management practices.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.46 | 0.33 | 1.17 | 1.06 | 1.09 |
| Inventory Turnover Ratio | 9.99 | 2.35 | 4.72 | 35.79 | 44.19 |
| Receivables Turnover Ratio | 5.08 | 1.37 | 2.88 | 16.86 | 16.44 |
| Days Sales in Inventory Ratio | 36.54 | 155.32 | 77.33 | 10.2 | 8.26 |
| Receivable Days | 71.85 | 266.42 | 126.74 | 21.65 | 22.2 |
| Capital Turnover Ratio | 1.32 | 0.34 | 0.69 | 0.84 | 0.7 |
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
The company's coverage ratios indicate its ability to meet its interest obligations. The interest coverage ratio suggests the company can manage its debt. However, these ratios need to be consistently monitored to ensure financial stability, especially if the company plans to increase its debt levels. Maintaining adequate coverage ratios is essential for sustaining financial health and investor confidence.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 3.07 | 6.32 | 3.25 | 42.67 | 5.63 |
| Equity Dividend Coverage Ratio | 0.02 | 20 | 2.5 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company demonstrates strong solvency. A low debt-to-equity ratio signals a conservative capital structure, while a reasonable debt ratio indicates a balanced mix of debt and equity financing. The interest coverage ratio suggests the company can comfortably meet its interest obligations. This indicates financial stability and a lower risk of financial distress. However, the company should continue to monitor its debt levels and interest expenses to maintain a healthy solvency position.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.56 | 0.56 | 0.27 | 0.42 | 0.31 |
| Debt to Equity Ratio | 1.27 | 1.27 | 0.37 | 0.72 | 0.45 |
| Equity Ratio | 0.44 | 0.44 | 0.73 | 0.58 | 0.69 |
| Debt To Asset Ratio | 0.36 | 0.34 | 0.09 | 0.34 | 0.26 |
Debt Ratio
Debt to Equity Ratio
Interest Coverage Ratio
The company's liquidity position cannot be reliably assessed due to missing data. A comprehensive liquidity analysis requires detailed information on current, quick, cash, and operating cash flow ratios to determine the company's ability to meet its short-term obligations. Without this information, it is challenging to provide a meaningful assessment of the company's financial health and stability.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.02 | 0.96 | 1.19 | 1.63 | 1.57 |
| Quick Ratio | 0.79 | 0.73 | 1.18 | 1.56 | 1.5 |
| Cash Ratio | 0.09 | 0.08 | 0.01 | 1.05 | 0.91 |
| Operating Cash Flow Ratio | 0.3 | 0.32 | 0.01 | 0.32 | 0.45 |
Current Ratio
Quick Ratio
Cash Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Aster DM Healthcare Ltd | 4.27 | 5.87 | Neutral | 864.00 | 5.17 | 427.00 |
The management effectiveness of Aster DM Healthcare presents a mixed picture. Revenue growth has been inconsistent, with significant declines in recent years partially offset by more recent quarterly improvements. Profitability has been volatile, influenced by other income and exceptional items. While improvements in operating profit margin are noted, the overall return on capital employed and equity remains modest. The increase in promoter holding indicates confidence, but a decrease in FII holding raises concerns. Overall, management is assessed as mixed due to inconsistent financial performance and moderate capital efficiency, balanced by positive strategic initiatives and ownership structure adjustments.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 41.88% | Indicates confidence |
| OPM (Sep 2024) | 20% | Improving operational efficiency | |
| CONS | Sales Growth (TTM) | -30% | Indicates revenue contraction |
| ROCE % (Mar 2024) | 4% | Suggests low capital productivity |
Financial Performance & Growth
Aster DM Healthcare's financial performance reveals inconsistent revenue and profit growth trends. While historical sales growth was robust, recent figures indicate a significant contraction, partially offset by recent quarterly improvements. Quarterly sales show a recovery in growth, with recent figures showing positive YOY growth. However, profit growth has been volatile, influenced significantly by 'Other Income' and 'Exceptional Items', which raises concerns about the sustainability of core operational profitability.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Sales Growth (%) | 40.1% | 15.2% | 9.5% | -70.8% | 23.54% |
| OPM (%) | 13.7% | 9.7% | 15.0% | 15.0% | 16.0% |
Capital Efficiency & Returns
The capital efficiency and returns for Aster DM Healthcare are modest. The Return on Capital Employed (ROCE) and Return on Equity (ROE) are relatively low, indicating that capital and shareholder funds are not being utilized very productively. The debt-to-equity ratio has fluctuated significantly, reflecting changes in the company's capital structure and financial leverage.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| ROCE % | 11.33% | 7.0% | 8.0% | 3% | 4% |
| ROE % | NA | NA | NA | NA | 3% |
Financial Health & Prudence
Aster DM Healthcare's financial health presents a mixed assessment. Debt levels have fluctuated significantly over the years. There was a sharp increase in borrowings in 2016, followed by fluctuations. The debt-to-equity ratio has varied, reflecting changes in the company's capital structure and financial leverage. Dividend payout has been inconsistent, with a recent payout in Mar 2024 but no consistent history of sharing profits with shareholders.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Borrowings | 827.3Cr | 27.9Cr | 47.7Cr | 52.8Cr | 60.7Cr | 17.5Cr |
| Dividend Payout % | 11.6% | 0.0% | 0.0% | 0.0% | 0.0% | 77.0% |
Shareholding & Ownership Structure
The shareholding pattern of Aster DM Healthcare indicates some positive trends. Promoter holding has increased, suggesting confidence in the company's prospects. However, there has been a notable decrease in FII (Foreign Institutional Investors) holding, which could be a concern. DII (Domestic Institutional Investors) holding has increased, which could offset the FII decrease to some extent.
| Shareholder Type | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 37.88% | 37.88% | 37.88% | 37.88% | 37.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.88% |
| FIIs | 10.95% | 11.03% | 11.44% | 11.77% | 42.49% | 38.63% | 38.82% | 40.22% | 41.00% | 33.48% | 27.08% | 23.86% |
| DIIs | 8.45% | 8.64% | 9.66% | 8.99% | 8.93% | 8.93% | 8.62% | 7.64% | 7.15% | 13.70% | 16.35% | 20.91% |
The risk assessment for Aster DM Healthcare is rated as Orange, indicating moderate risk. Segment performance volatility is a key concern, given the significant revenue drop due to business restructuring. The recent increase in 'other liabilities' could create financial inflexibility. These factors contribute to a risk profile that requires vigilance and proactive management.
Segment performance volatility
Aster DM Healthcare has experienced significant segment performance volatility. The consolidated sales have dropped considerably. This decline is primarily due to the sale of the Gulf business. This restructuring has resulted in a notable contraction in overall revenue, impacting the company's financial stability.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Sales | 10,253 | 2,994 | 3,699 |
Accounting quality red flags
The accounting quality of Aster DM Healthcare shows some fluctuations that merit attention. There is a notable increase in ‘Other Liabilities,’ from ₹4,687 Cr in Mar 2023 to ₹12,039 Cr in Mar 2024. Additionally, 'Other Assets' significantly increased from ₹5,425 Cr in Mar 2023 to ₹14,620 Cr in Mar 2024. Significant increase in 'Other Income' and 'Exceptional Items'.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Other Liabilities | 3,661 | 4,687 | 12,039 |
| Other Assets | 4,470 | 5,425 | 14,620 |
| Other Income | 51 | 353 | 32 |
Foreign exchange or interest rate exposure
Aster DM Healthcare's exposure to foreign exchange and interest rate fluctuations can be inferred from its financial statements. The company's operations span multiple geographies, exposing it to currency risks. Additionally, interest expenses are present, which could be impacted by interest rate volatility.
Regulatory compliance cost trends
Regulatory compliance costs for Aster DM Healthcare can be indirectly assessed through its expenses. Employee costs and other costs are the major part of expenses. These costs may include expenses to adhere with regulatory norms.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe